Form 4: DexCom Director Bridgette P. Heller Sells Shares Under 10b5-1 Plan

Director Bridgette P. Heller sold 352 shares of DexCom Inc. common stock at $70.33 per share on March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 17, 2025, Bridgette P. Heller, a director of DexCom Inc., sold 352 shares of common stock at a price of $70.33 per share.
• The sale was executed under a 10b5-1 trading plan adopted on February 25, 2024, which allows for the orderly disposition of shares.
• Following the transaction, Ms. Heller beneficially owns 22,997 shares of DexCom Inc., which includes 2,618 unvested restricted stock units granted on May 22, 2024, that will vest on the earlier of the one-year anniversary or the date of DexCom Inc's 2025 Annual Meeting of Stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged plan. There is no indication of positive or negative implications for the company.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating an orderly and planned disposition of shares.

Industry Context

Sales by insiders are a normal part of corporate activity. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific inside information.

Stakeholder Impact

• The sale of shares by a director could have a minor psychological impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

DexCom, Director, Share Sale, 10b5-1 Plan, DXCM, Beneficial Ownership, Securities, Form 4